-

05:24:40 PM

IMGN Stock News

IMGN - Immunogen, Inc.

09/29/23 5:00 PM

Nasdaq : IMGN

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc.,, a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the compensation committee of the Company’ s Board of Directors approved, effective as of September 25, 2023, grants of non-qualified stock options to purchase 258,300 shares of its common stock and restricted stock units covering...

RHEA-AI

very positive

09/28/23 7:00 AM

Nasdaq : IMGN

ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE ® compared to chemotherapy in patients with folate receptor alpha- positive platinum-resistant ovarian cancer.

RHEA-AI

neutral

09/18/23 5:00 PM

Nasdaq : IMGN

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc.,, a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen’ s Senior Vice President and Chief Financial Officer, the compensation committee of the Company’ s Board of Directors...

RHEA-AI

very positive

09/18/23 6:30 AM

Nasdaq : IMGN

management

ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer

"We have made significant progress in the business this year with the successful launch of ELAHERE ®, the positive MIRASOL results intended to support ELAHERE's expansion into Europe as well as full approval in the US, and the progression of our novel pipeline of ADCs. Prior to this role, she launched the global health business unit as Chief Financial Officer in...

RHEA-AI

positive

09/05/23 4:30 PM

Nasdaq : IMGN

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc.,, a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the compensation committee of the Company’ s Board of Directors approved, effective as of August 31, 2023, grants of non-qualified stock options to purchase an aggregate of 59,260 shares of its common stock and restricted stock units...

RHEA-AI

very positive

08/28/23 6:30 AM

Nasdaq, NYSE : IMGN, TAK

ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan. "As a leader in the development and commercialization of novel products in oncology for more than...

RHEA-AI

positive

08/01/23 4:30 PM

Nasdaq : IMGN

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc.,, a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the compensation committee of the Company’ s Board of Directors approved, effective as of July 31, 2023, grants of non-qualified stock options to purchase an aggregate of 20,600 shares of its common stock and restricted stock units...

RHEA-AI

very positive

07/31/23 6:35 AM

Nasdaq : IMGN

ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen.

RHEA-AI

positive

07/31/23 6:30 AM

Nasdaq : IMGN

earnings

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.. Generated $77.4 million in ELAHERE ® net sales for the quarter ended June 30, 2023. Announced positive data from the confirmatory Phase 3...

RHEA-AI

positive

07/27/23 4:30 PM

Nasdaq : IMGN

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston, MA. The presentation is scheduled for August 10, 2023 at 10:00 am ET. A webcast of the presentation will be...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

IMGN Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.immunogen.com/
Security nameImmunogen, Inc.
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUS

About Immunogen, Inc.

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.